How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach
详细信息    查看全文
  • 作者：Ali Rezaie ; Mark Pimentel ; Satish S. Rao
  • 关键词：Small intestinal bacterial overgrowth (SIBO) ; Glucose breath test ; Lactulose breath test ; Small intestinal aspiration and culture ; Antibiotics ; Elemental diet ; Promotility drugs
  • 刊名：Current Gastroenterology Reports
  • 出版年：2016
  • 出版时间：January 2016
  • 年：2016
  • 卷：18
  • 期：2
  • 全文大小：1,949 KB
  • 参考文献：1.Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chron Dis. 2013;4:223–31.CrossRef
    2.Gutierrez IM, Kang KH, Calvert CE, et al. Risk factors for small bowel bacterial overgrowth and diagnostic yield of duodenal aspirates in children with intestinal failure: a retrospective review. J Pediatr Surg. 2012;47:1150–4.PubMed PubMedCentral CrossRef
    3.Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978–90.PubMed PubMedCentral CrossRef
    4.Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44:672–5.PubMed CrossRef
    5.••
Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37:1103–11. This study showed that abscent phase III MMCs is a risk factor for bacterial overgrowth.PubMed PubMedCentral CrossRef
6.Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–9.PubMed CrossRef
7.Husebye E, Skar V, Hoverstad T, et al. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology. 1995;109:1078–89.PubMed CrossRef
8.Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci. 2010;6:49–55.PubMed PubMedCentral CrossRef
9.Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6:759–64.PubMed CrossRef
10.Giamarellos-Bourboulis E, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50:1076–87.
11.Yang CY, Chang CS, Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol. 1998;33:867–71.PubMed CrossRef
12.Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98:1362–70.PubMed CrossRef
13.Basseri RJ, Basseri B, Pimentel M, et al. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol (N Y). 2012;8:22–8.
14.George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis Sci. 2014;59:645–52.PubMed CrossRef
15.Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol. 2015;21:10609–20.PubMed PubMedCentral CrossRef
16.Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–2.PubMed PubMedCentral CrossRef
17.Signoretti M, Stigliano S, Valente R, et al. Small intestinal bacterial overgrowth in patients with chronic pancreatitis. J Clin Gastroenterol. 2014;48 Suppl 1:S52–55.PubMed CrossRef
18.Strid H, Simren M, Stotzer PO, et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67:129–37.PubMed CrossRef
19.Patricio Ibanez MP, Melmed GY, Ippoliti A, Targan SR, Vasiliauskas EA. Fatigue and abdominal bloating predict small intestinal bacterial overgrowth (SIBO) in patients with ulcerative colitis (UC). Gastroenterology. 2008;134:A-350.
20.Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38:674–88.PubMed CrossRef
21.Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443–54.PubMed CrossRef
22.••
Baker JC, Saad WRJ. Common gastrointestinal symptoms do not predict the results of glucose breath testing in the evaluation of suspected small intestinal bacterial overgrowth. Am J Gastroenterol. 2015;110:S1004. Using a large database of breath tests, this study showed that bacterial overgrowth cannot be predicted by symptoms.
23.Levitt MD, Bond Jr JH. Volume, composition, and source of intestinal gas. Gastroenterology. 1970;59:921–9.PubMed
24.Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55:297–303.PubMed PubMedCentral CrossRef
25.•Rezaie ACK, Chang C, Kemmerly T, Pimentel M. Methane on breath test predicts altered rectal sensation during high resolution anorectal manometry. Gastroenterology. 2014;146:S-721. This study showed that visceral sensitivity assessed by graded rectal balloon distension has direct correlation with bacterial overgrowth.CrossRef
26.Kunkel D, Basseri RJ, Makhani MD, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612–8.PubMed CrossRef
27.Chatterjee S, Park S, Low K, et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102:837–41.PubMed CrossRef
28.••Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481–9. This study showed that glucose breath test has 84% specificity and 42% sensitivity in diagnosis of SIBO as compared to duodenal aspiration.PubMed CrossRef
29.Erdogan A, Lee YY, Badger C, Hall P, O'Banion M, Rao SSC. What is the optimal threshold for an increase in hydrogen and methane levels with glucose breath test (GBT) for detection of small intestinal bacterial overgrowth (SIBO)? Gastroenterology. 2014;146(Supplement 1):S-532.CrossRef
30.Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925–34.PubMed CrossRef
31.Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–6.PubMed CrossRef
32.Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–9.PubMed
33.Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Euro Rev Med Pharmacol Sci. 2009;13:111–6.
34.Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engle J Med. 2011;364:22–32.CrossRef
35.Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (N Y). 2015;11:1–19.
36.Pourmorady JS, Rezaie E, Pimentel MA. Breath testing for small intestinal bacterial overgrowth in irritable bowel syndrome: a meta-analysis. Am J Gastroenterol. 2015;110:S762.
37.Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547–50.PubMed
38.••Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59:1278–85. This randomized controlled trial showed that combination of rifaximin and neomycin is more effective than neomycin alone in treatment of constipation associated with methane-predominat SIBO.PubMed CrossRef
39.Gottlieb K, Wacher V, Sliman J, Pimentel M. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther. 2015;43(2):197–212.PubMed CrossRef
40.Triantafyllou K, Chang C, Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil. 2014;20:31–40.PubMed PubMedCentral CrossRef
41.Winitz M, Adams RF, Seedman DA, et al. Studies in metabolic nutrition employing chemically defined diets. II. Effects on gut microflora populations. Am J Clin Nutr. 1970;23:546–59.PubMed
42.Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49:73–7.PubMed CrossRef
43.Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3:16–24.PubMed PubMedCentral CrossRef
44.Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. Altern Med Rev. 2002;7:410–7.PubMed
45.Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103:2031–5.PubMed CrossRef
46.Code CF, Marlett JA. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J Physiol. 1975;246:289–309.PubMed PubMedCentral CrossRef
47.Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158–66.PubMed PubMedCentral CrossRef
48.Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–43.PubMed CrossRef
49.Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9:271–85.PubMed CrossRef
50.Nasr I, Rao SS, Attaluri A, et al. Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study. Indian J Gastroenterol. 2009;28:136–42.PubMed CrossRef
51.Madrid AM, Hurtado C, Venegas M, et al. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96:1251–5.PubMed CrossRef
52.Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009;5:435–42.
53.Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93–100.PubMed CrossRef
54.Law D, Conklin J, Pimentel M. Lactose intolerance and the role of the lactose breath test. Am J Gastroenterol. 2010;105:1726–8.PubMed CrossRef
55.Rao SS, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–70.PubMed CrossRef
56.Peppin J, Pappagallo M, Barrett A, et al. Effect of subcutaneous methylnaltrexone on patient-reported outcomes in advanced illness patients with opioid-induced constipation. J Pain. 2013;1:S62.CrossRef
57.Chey W, Tack J, Webster L, et al. Naloxegol symptom responder rates in patients with opioid-induced constipation: results from two prospective, randomized controlled trials. Am J Gastroenterol. 2013;108:S570.
58.Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912–21.PubMed PubMedCentral CrossRef
59.Spierings EL, Drossman DA, Cryer BL, et al. A pooled analysis of response to lubiprostone in patients with opioid-induced constipation receiving non-methadone opioids versus methadone. Gastroenterology. 2014;1:S-360.CrossRef
60.Hwang HJ, An MS, Ha TK et al. All the commercially available adhesion barriers have the same effect on adhesion prophylaxis? A comparison of barrier agents using a newly developed, severe intra-abdominal adhesion model. Int J Colorectal Dis 2013;28:1117–1125.
61.Reinstein E, Pimentel M, Pariani M, et al. Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literature. Eur J Med Genet. 2012;55:548–51.PubMed PubMedCentral CrossRef
62.Raj SR, Black BK, Biaggioni I, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111:2734–40.PubMed CrossRef
63.Madsbad S. A review of head-to-head comparisons of GLP-1 receptor agonists. Diabetes Obes Metab. 2015;6(1):19–28.
64.Ockeloen LE, Deckers-Kocken JM. Short- and long-term effects of a lactose-restricted diet and probiotics in children with chronic abdominal pain: a retrospective study. Complement Ther Clin Pract. 2012;18:81–4.PubMed CrossRef
65.Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–57.PubMed CrossRef
66.Rezaie A, Pimentel M. Probiotics for antibiotic-associated diarrhea: PLACIDE swings the pendulum. Gastroenterology. 2014;146:1822–3.PubMed CrossRef
  • 作者单位：Ali Rezaie (1) (3)
    Mark Pimentel (1)
    Satish S. Rao (2)

    1. GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, 8730 Alden Drive, Thalians Bldg, #E226, Los Angeles, CA, 90048, USA
    3. David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, USA
    2. Division of Gastroenterology/Hepatology, Medical College of Georgia, Augusta University, Augusta, GA, USA
  • 刊物主题：Gastroenterology;
  • 出版者：Springer US
  • ISSN：1534-312X
    • 文摘
    Small intestinal bacterial overgrowth (SIBO) is characterized by an excessive amount of bacteria in the small intestine and a constellation of symptoms that include bloating, pain, gas, and diarrhea. Although known for many decades, there is a lack of consensus and clarity regarding the natural history and methods for its diagnosis. Several tests have been proposed, including the glucose breath test, lactulose breath test, small intestinal aspiration and culture, and others. However, there is a lack of standardization of these tests and their interpretation. Treatment of SIBO remains empirical; generally, broad spectrum antibiotics are recommended for 2 weeks (amoxicillin, rifaximin, ciprofloxacin, etc.) but evidence for their use is fair. Clearly, there is a strong need to develop a systematic approach for the management of SIBO and to perform multicenter clinical trials for the treatment of SIBO. In this review, we will discuss the current evidence for the diagnosis and treatment of SIBO, which includes (1) elimination/modification of the underlying causes, (2) induction of remission (antibiotics and elemental diet), and (3) maintenance of remission (promotility drugs, dietary modifications, repeat or cyclical antibiotics). Keywords Small intestinal bacterial overgrowth (SIBO) Glucose breath test Lactulose breath test Small intestinal aspiration and culture Antibiotics Elemental diet Promotility drugs
    NGLC 2004-2010.National Geological Library of China All Rights Reserved.
    Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
    For exchange or info please contact us via email.